RT for Cervical Adenocarcinoma/adenosquamous Carcinoma

NCT06741046 | Active Not Recruiting

• 1 other identifier: ATTRACT-Retro
• Study Type: observational
• Target: 400
• Locations: 1 country
• Sites: 1

Brief Summary

The purpose of this study was to retrospectively analyze patients with cervical adenocarcinoma/adenosquamous carcinoma who had been admitted to our hospital. Approximately 500 cases of cervical adenocarcinoma were planned to be included, summarize the disease characteristics, treatment regimens, and recurrence patterns of the patients, and analyze the association between treatment regimens and recurrence patterns and prognosis.

Conditions

Uterine Neoplasms; Genital Neoplasms, Female

Keywords

cervical adenocarcinoma; cervical adenosquamous carcinoma

Outcome Measures

Primary Outcomes (1)

• Local control rate

  Tumor control rate in the cohort after treatment

  local control rates at 2 years or 3 years after the initial treatment

Secondary Outcomes (2)

• Progress free survival

  2 years after initial treatment

• Overall survival

  2 years after initial treatment

Study Arms (2)

Radical surgery group

Patients who received radical surgery for cervical cancer in Peking Union Medical College Hospital

Concurrent chemoradiotherapy group

Patients who received concurrent chemoradiotherapy in Peking Union Medical College Hospital

Eligibility Criteria

• Age: 18 Years - 80 Years
• Sex: female
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Female patinets diagnosed with cervical adenocarcinoma or adenosquamous carcinoma receiving CCRT or RT after complete surgery

You may qualify if:

• a) Pathological diagnosis of cervical adenocarcinoma; b) Age 18-80 years old; c) Karnofsky score≥60 points; e) Complete blood count, and comprehensive metabolic panel meet the conditions for CCRT or RT after surgery; f) No metal implants in the body, and can perform MRI examination; g) Willing to participate in this study and provide written informed consent. -

You may not qualify if:

• Patients who have received pelvic radiotherapy before;
• Patients whose target tumors have been treated before (chemotherapy, immunotherapy, surgical treatment, etc.);
• Allergy to iodine contrast agent;
• Participating in other clinical studies that may affect the results of this study (determined by the principal investigator);
• f) Serious diseases that may significantly affect compliance with clinical trials, such as unstable heart disease, kidney disease, chronic hepatitis, poorly controlled diabetes, and mental illness that require treatment; g) Other situations that the investigator believes are not suitable for participation in this clinical study.

Sponsors & Collaborators

• Peking Union Medical College Hospital: lead

Study Sites (1)

Peking Union Medical College Hospital

Beijing, China

Location

Biospecimen

Retention: SAMPLES WITH DNA

biopsy

MeSH Terms

Conditions

Uterine Neoplasms; Genital Neoplasms, Female

Condition Hierarchy (Ancestors)

Urogenital Neoplasms; Neoplasms by Site; Neoplasms; Uterine Diseases; Genital Diseases, Female; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Urogenital Diseases; Genital Diseases

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Chief Assistant for Department of Radiotherapy

Study Record Dates

• First Submitted: December 16, 2024
• First Posted: December 18, 2024
• Study Start: June 1, 2014
• Primary Completion: June 1, 2025
• Study Completion (Estimated): June 1, 2027
• Last Updated: December 18, 2024

Record last verified: 2024-11

Locations

CN (1)